SECsense Logo

Oncolytics Biotech Inc. February 2025 SEC Form 6-K Report Insights

$ONCY
Form 6-K
Filed on: 2025-02-10
Source
Oncolytics Biotech Inc. February 2025 SEC Form 6-K Report Insights

Here are the key insights extracted from the provided section of the financial report for Oncolytics Biotech Inc.:

  1. Filing Type: The document is a Form 6-K, which is a report of foreign private issuer submitted to the SEC.
  2. Reporting Period: The report covers the month of February 2025.
  3. Commission File Number: The file number associated with this report is 001-38512.
  4. Company Information:
  • Name: Oncolytics Biotech Inc.
  • Address: Suite 804, 322 11th Avenue SW, Calgary, Alberta, Canada T2R 0C5.
  1. Regulatory Compliance:
  • The registrant indicated whether it files annual reports under Form 20-F or Form 40-F.
  • The report includes a note that Form 6-K may be submitted in paper format under certain conditions specified by Regulation S-T.
  1. Signatures:
  • The report has been signed by Kirk Look, the Chief Financial Officer of Oncolytics Biotech Inc., on February 7, 2025.
  1. Exhibits:
  • The report references an exhibit (99.1) that includes a Press Release linked within the document.

These points summarize the essential details of the report, including its purpose, compliance with regulatory requirements, and key company identifiers.